Tech Company Financing Transactions
Immunic Therapeutics Funding Round
On 1/5/2024, Immunic Therapeutics received $240 million in funding from BVF Partners, Adage Capital Management and Avidity Partners.
Transaction Overview
Company Name
Announced On
1/5/2024
Transaction Type
Venture Equity
Amount
$240,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The Company intends to use the net proceeds from the private placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-856 and IMU-381, and for other general corporate purposes.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
1200 Avenue of the Americas 200
New York, NY 10036
USA
New York, NY 10036
USA
Phone
Website
Email Address
Not Recorded
Overview
Immunic is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Duane Nash
Chief Executive Officer
Daniel Vitt
Chief Financial Officer
Glenn Whaley
Chief Medical Officer
Andreas Muehler
Chief Scientific Officer
Hella Kohlhof
VP - Bus. Development
Patrick Walsh
VP - General Counsel
Inderpal Singh
Browse more venture capital transactions:
Prev: 1/5/2024: Vico Therapeutics venture capital transaction
Next: 1/5/2024: Nabla venture capital transaction
Share this article
About Our VC Transactions Data
We record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs